Summary
The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%. Recently, interferon alpha (IFNα) was used for treatment of this disease in several studies which also demonstrated response rates of 15%. In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFNα 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial. The rIFNα 2C (2MU) was given s.c. 5 times per week for 8–12 weeks and subsequently once weekly until week 48. In the combined treatment, 750 mg MPA was given p. o. daily until week 48 in addition to the IFN as described. The overall response rate in 93 evaluable patients was 5.4%, corresponding to 2 complete and 3 partial responses. Median survival was 7 months in both treatment groups. These data confirm the ineffectivity of low IFN doses for treatment of RCC. The low response rate is not increased by addition of MPA to IFN. The analysis of other IFN studies suggests that not only IFN doses but also IFN sources may influence response rates in metastatic RCC.
Similar content being viewed by others
References
Bassil B, Dosoretz DE, Prout GR (1985) Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 134:450–454
Berg HW van den, Clarke R (1985) Does human recombinant interferon alfa potentiate the anti-proliferative effect of tamoxifen towards oestrogen receptor positive human breast cancer cells. Br J Cancer 52:428
Bloom HJG (1983) Hormone induced and spontaneous regression of metastatic renal cancer. Cancer 32:1066–1071
Bodey GP (1979) Current status of chemotherapy in metastatic renal carcinoma. In: Johnson DE, Samuels ML (eds) Cancer of the genitourinary tract. Raven Press, New York, pp 67–72
Borden EC, Holland JF, Dao TL et al. (1982) Leukocyte-derived interferon (alpha) in human breast carcinoma. Ann Intern Med 97:1–6
Canellos GP (1985) Interferon in the treatment of malignant lymphoma. Semin Oncol (Suppl) 5:25–29
DeKernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma—a computer analysis. J Urol 120:148–152
DeKernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130:1063–1066
Edsmyr F, Esposti PL, Andersson L, Steineck G, Lagergren C, Strander H (1985) Interferon therapy in disseminated renal cell carcinoma. Radiother Oncol 4:21–26
Einzig AI, Krown SE, Oettgen HF (1984) Recombinant leukocyte A interferon (rIFN-alpha A) in renal cells cancer. Proc Am Soc Clin Oncol 3:54
Everson TC, Cole WM (1966) Spontaneous regression of cancer. Saunders, Philadelphia, pp 11–97
Figlin RA, DeKernion JB, Maldazys J, Sarna G (1985) Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I–II trial. Cancer Treat Rep 69(3):263–267
Fossa SD, Telhaug R, Wahlqvist R (1984) Spontanremisjion av metastaser fra cancer renis. Tidsskr Nor Laegeforen 104:583–585
Fossa SD, DeGaris ST, Heier MS, Flokkmann A, Lien HH, Salveson A, Moe B (1986) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57 (8):1700–1704
Guterman JU, Blumenschein GR, Alexanian R, et al. (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Inern Med 93:399–406
Gutterman JU, Fine S, Quesada JR, et al. (1982) Recombinant leukocyte A interferon: pharmaco-kinetics, single dose tolerance, and biologic effects in cancer patient. Ann Intern Med 96:549–556
Harris DT (1983) Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 4:422–430
Holland JM (1973) Cancer of the kidney: Natural history and staging. Cancer 32:1030
Horoszewicz JS, Leong SS, Carter WA (1979) Non cycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206:1091–1093
Hrusheksy WJ, Murphy GP (1977) Current status of therapy of advanced renal carcinoma. J Surg Oncol 9:277–288
Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, Ernstoff MS, Gordon L, Lutes R, Bonomi P, Lytton B, Cobleigh M, Taylor SJ (1985) IV. A randomized study of low and high doses leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society Collaborative Trial. Cancer Res 45:863–871
Krown SE (1985) Therapeutic options in renal-cell carcinoma. Semin Oncol (Suppl) 5:13–17
Krown SE, Einzig AI, Abramson JD, Oettgen HF (1983) Treatment of advanced renal cell cancer (RCC) with recombinant leukocyte A interferon (rIFN-Alpha A). Proc Am Soc Clin Oncol 2:58
Krown SE, Real FX, Vadhan-Raj S, Cunningham-Rundles S, Krim M, Wong G, Oettgen HF (1986) Kaposi's sarcoma and the acquired immune deficiency syndrome. Cancer 57 (8):1662–1665
Legha SS (1986) Interferons in the treatment of malignant melanoma. Cancer 57 (8):1675–1677
Marumo K, Murai M, Hayakawa M, Tazaki H (1984) Human lymphoblastoid interferon theraphy for advanced renal cell carcinoma. Urology 24 (6):567–572
Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA (1978) Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449–1453
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Montie JE, Stewart BH, Straffon RA (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117:272–275
Muss HB, Welander C, Caponera M, Reavis K, Cruz MJ, Cooper R, Jackson DV, Richards F, Stuart JJ Spurr CL, White DR, Zekan PJ, Capizzi RL (1985) Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 69 (6):721–722
Neidhart JA (1986) Interferon therapy for the treatment of renal cancer. Cancer 57 (8):1696–1699
Neidhart J, Gagen M, Kisner D (1984) Therapy of renal cancer with low (LD), intermediate (ID), and high (HD) dose regimens of human lymphoblastoid interferon (HBLJ; Wellferon). Proc Am Soc Clin Oncol 3:60
Neidhart J, Gagen M, Kisner D, Tuttle R, Whisnant J (1984) Therapy of renal cancer with low (LD), intermediate (ID), and high (HD) dose regimens of human lymphoblastoid interferon (HBLI; Wellferon). Proc Am Soc Clin Oncol 3:60
Neidhart JA, Gagen MM, Young D, Tuttle R, Melink TJ, Ziccarrelli A, Kisner D (1984) Interferon-alpha therapy of renal cancer. Cancer Res 44:4140–4143
Pouilart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Billiau A (1982) Administration of fibroblast interferon to patients with advanced breast cancer: Possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol 10:929–935
Porzsolt F (1986) Primary treatment of hairy cell leukemia: Should IFN therapy replace sphlenectomy? Blut 52:265–272
Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43:940–947
Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18
Quesada JR, Hawkins M, Horning S, et al. (1984) A collaborative phase I–II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77:427–432
Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3 (11):1522–1528
Ryd W, Hagmar B, Lundgren E, Stranngard O (1979) Discrepant effects of interferon on murine syngeneic ascites tumors and their solid metastasizing counterparts. Int J Cancer 23:397–401
Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 314 (17):1065–1069
Trump D, Harris J, Tuttle R (1984) Phase II trial of high dose human lymphoblastoid interferon (Wellferon), in advanced renal cell carcinoma (RCC): an ECOG pilot (Abstr. C-600). Proc Am Soc Clin Oncol 3:153
Umeda T, Niijima T (1986) Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 58:1231–1235
Vugrin D, Hood L, Taylor W, Laszlo J (1985) Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma. Cancer Treat Rep 69 (7–8):817–820
Author information
Authors and Affiliations
Additional information
This study was supported by Boehringer Ingelheim and Upjohn Heppenheim, West-Germany
Rights and permissions
About this article
Cite this article
Porzsolt, F., Messerer, D., Hautmann, R. et al. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. J Cancer Res Clin Oncol 114, 95–100 (1988). https://doi.org/10.1007/BF00390492
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00390492